Name of Policy:	Intravenous Use of Iodinated Contrast Agents within Cardiovascular Lab		
Policy Number:	3364-102-07	MEDICAL CENTER	
Department:	Cardiovascular Lab	WILDIOAL CLITTLE	
Approving Officer:	Chief Operating Officer- UTMC		
Responsible Agent:	Director, Cardiovascular Services		
Scope:	University of Toledo Medical Center	Effective Date: 03/01/2022 Initial Effective Date: 05/01/2019	
New policy proposal Minor/technical revision of existing policy Major revision of existing policy X Reaffirmation of existing policy			

1. Introduction

"Various forms of contrast media have been used to improve medical imaging. Their value has long been recognized, as attested to by their common daily use in imaging departments worldwide. Like all other pharmaceuticals, however, these agents are not completely devoid of risk." – ACR Manual on Contrast Media-Version 10.1, 2015.

The term "low-osmolality" (LOCM) in reference to radiographic iodinated contrast media is intended to encompass both low-osmolality and iso-osmolality media, the former having osmolality approximately twice that of human serum and the latter having osmolality approximately that of human serum at conventionally used iodine concentrations for intravenous injection.

- Visipage (Iodixanol) injectable contrast will be the default injectable contrast for all procedures that occurs within the Cardiovascular Lab.
- Volumes used will be at the discretion of the physician.

Approved by: /s/	03/18/2022	Review/Revision Date: 05/01/2019 03/2020		
Todd Korzec, RN, BSN	Date	03/2022		
Director, Cardiovascular Services				
/s/	03/18/2022			
Ehab Eltahawy, MD, MPH	Date			
Medical Director, Cardiovascular Lab				
/s/ Christine Stesney-Ridenour, FACHE	03/18/2022 Date			
Chief Operating Officer- UTMC	Bate			
Review/Revision Completed By: Todd Korzec	Next Review Date: 03/1/2025			
Policies Superseded by This Policy:				